Is MannKind Corporation (MNKD) a Buy, Sell, or Hold?
MannKind Corporation
NASDAQ:MNKD
$4.035 USD
$0.15 (3.99%)
- Volume
- 3.74M
- Average Volume
- 5.7M
- Market Capitalization
- $1.25B
- P/E Ratio
- -52.20
- Dividend Yield
- 0.00%
- Price Target
- $8.50
- Year High
- $6.51
- Year Low
- $2.23
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.87
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Michael E. Castagna |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | MNKD |
| CUSIP | 56400P706 |
| CIK | 0000899460 |
| Web | https://www.mannkindcorp.com |
| Phone | 818 661 5000 |
| Currency | USD |
| Employees | 592 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -7.38 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.87 |
| Quick Ratio | 1.50 |
| Cash Ratio | 0.39 |
Sales & Book Value
| Annual Sales | $348.97M |
| Price / Sales | 3.46 |
| Cash Flow | 0.04 |
| Price / Cash Flow | 98.02 |
| Price / Book | -21.01 |
Price Target and Rating
| Average Stock Price Forecast | $8.50 |
| High Stock Price Forecast | $11.00 |
| Low Stock Price Forecast | $6.00 |
| Forecast Upside/Downside | -52.53% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 19 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $0.02 |
| Trailing P/E Ratio | -52.20 |
| PEG Ratio | 0.29 |
| P/E Growth | 0.29 |
| Net Income | $5.86M |
| Net Margin | -6.63% |
| Pretax Margin | -7.92% |
| Return on Equity | 45.59% |
| Return on Assets | -3.21% |
Financials Score
| AltmanZ Score | -4.43 |
| Piotroski Score | 2.00 |
| Working Capital | 116.6M |
| Total Assets | 744.4M |
| Ebit | 10.53M |
| Market Cap | 1.2B |
| Total Liabilities | 803.6M |
Poll Results
About MannKind Corporation (NASDAQ:MNKD) Stock
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptad ... il), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
2026-06-23 09:00:00
Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
2026-06-05 19:35:00
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use
2026-06-05 19:35:00
Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes New data and real-world findings further emphasize pediatric safety, glycemic control and treatment satisfaction Exploratory analysis of inhaled insulin used with AID systems provides insight on the impact of total daily dose algorithms Data from randomized cross-over trial supports safety and efficacy of inhaled insulin as an alternative to RAA in gestational diabetes DANBURY, Conn.
2026-06-03 06:05:00
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2
MannKind At An Inflection Point: Pediatric Expansion Drives The Story
2026-06-02 22:40:35
MannKind gains FDA approval for Afrezza pediatric use, expanding its differentiated inhaled insulin therapy to children aged 6+ with type 1 or 2 diabetes. I see Afrezza's pediatric label extension as a durable growth inflection, targeting a concentrated 360,000-patient U.S. base and 30,000 annual inflow, with an efficient commercial strategy. MNKD estimates a 23–37% pediatric market share, translating to a $300–500 million revenue opportunity, with gradual adoption expected to accelerate meaningfully by 4Q26 and into 2027.
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market
2026-05-30 23:07:54
MannKind NASDAQ: MNKD said the U.S. Food and Drug Administration has approved Afrezza for pediatric patients with diabetes ages 6 and older, expanding the inhaled mealtime insulin's label into children and adolescents.
2026-05-29 19:24:04
MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
2026-05-29 14:00:00
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes.
Frequently Asked Questions
-
What is the current MannKind Corporation (MNKD) stock price?
-
MannKind Corporation(NASDAQ:MNKD) stock price is $4.035 in the last trading session. During the trading session, MNKD stock reached the peak price of $6.51 while $2.23 was the lowest point it dropped to. The percentage change in MNKD stock occurred in the recent session was 3.99% while the dollar amount for the price change in MNKD stock was $0.15.
-
MNKD's industry and sector of operation?
-
The NASDAQ listed MNKD is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of MNKD?
-
Stuart A. Tross | Chief People & Workplace Officer
Christopher Prentiss | Chief Financial Officer
Ajay Ahuja | Executive VP & Chief Medical Officer
David Thomson | Executive Vice President, General Counsel & Secretary
Michael E. Castagna | Chief Executive Officer & Director -
How many employees does MNKD have?
-
Number of MNKD employees currently stands at 592. MNKD operates from 30930 Russell Ranch Road, Danbury, CA 91362, US.
-
Link for MNKD official website?
-
Official Website of MNKD is: https://www.mannkindcorp.com
-
How do I contact MNKD?
-
MNKD could be contacted at phone #818 661 5000 and can also be accessed through its website. MNKD operates from 30930 Russell Ranch Road, Danbury, CA 91362, US.
-
How many shares of MNKD are traded daily?
-
The average number of MNKD shares traded daily for last 3 months was 5.7M.
-
What is the market cap of MNKD currently?
-
The market value of MNKD currently stands at $1.25B with its latest stock price at $4.035